Loading
A phase 2 trial in triple-negative breast cancer, run by Henan Cancer Hospital, now recruiting.
Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC is a phase 2, randomised interventional study registered as NCT06817525 by Henan Cancer Hospital, with a registry enrolment figure of 64 participants, started 2024-11-06 and due to reach its primary completion in 2026-05-31. Interventions recorded: 6*Nab-P (d 1)+6*Cb ( d 1)+6*PD1 (d 1); 6*Nab-P (d 1,8,15)+6*Cb ( d 1)+6*PD1 (d 1). Conditions listed: Triple-negative Breast Cancer. Sites: China. No results are recorded here; the registry entry is the source.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.